Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
NSI-189
Investigational neurogenic small molecule often discussed in nootropic circles despite limited human data.
Tier Cmedium risk
02· Subject
Semax
ACTH fragment analogue with preclinical neurotrophic signaling and limited clinical stroke/cognition data.
Tier B-Cmed-high risk
01 · At a glance
| Decision factor | NSI-189 | Semax | Selank |
|---|---|---|---|
| Primary fit | cognitive & neuroprotection and anxiety & mood comparisons | cognitive & neuroprotection and anxiety & mood comparisons | cognitive & neuroprotection and sleep & relaxation comparisons |
| Evidence | Tier C | Tier B-C | Tier B-C |
| Risk | medium | med-high | med-high |
| Experience level | advanced | intermediate | intermediate |
| Budget tier | mid | mid | mid |
| Administration route | oral | intranasal | intranasal |
02 · Use case & timing
| Decision factor | NSI-189 | Semax | Selank |
|---|---|---|---|
| Goal fit | Cognitive & Neuroprotection, Anxiety & Mood | Cognitive & Neuroprotection, Anxiety & Mood | Cognitive & Neuroprotection, Sleep & Relaxation, Anxiety & Mood |
| What users compare it for | Possible mood and cognitive-support effects remain speculative outside limited early human studies. | Neurotrophic signaling; cognitive/neuroprotection narratives from Russian/EE clinical literature. | Anxiolytic/calm focus effects reported in limited clinical settings. |
| Onset timeline | Any central effects would be expected over weeks rather than days. | Gene expression changes within hours (animal); clinical stroke outcomes are longer-horizon. | Some rapid responders described in clinical abstracts, but not broad RCT-grade evidence. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | NSI-189 | Semax | Selank |
|---|---|---|---|
| Adverse effects | Limited human safety base; mild insomnia or GI upset reported in small studies. | Immunogenicity/impurity concerns (FDA); limited Western safety framing. | Limited Western regulatory data; higher scrutiny warranted. |
| Contraindications | No clear formal contraindications; treat as an experimental CNS-active compound. | No established label. | No established label. |
| Interaction notes | Avoid confident multi-nootropic stacking claims because mechanistic overlap and safety data are limited. | Unknown; avoid claiming synergy with SSRIs/benzodiazepines without data. | Animal diazepam interaction explored; do not translate to human guidance. |
| Regulatory status | Investigational | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution | FDA compounding caution |
| WADA status | Not listed | Status unclear | Status unclear |
04 · Age & monitoring
| Decision factor | NSI-189 | Semax | Selank |
|---|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64, 65+ | No age guidance yet |
| Life-stage note | Not yet documented | Usually discussed for adult cognitive or recovery support rather than youth-oriented performance enhancement. | Not yet documented |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | NSI-189 | Semax | Selank |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | €13.76 | €20.64 |
| Estimated monthly cost | No reliable estimate yet | €27.52 | €27.52 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | NSI-189 | Semax | Selank |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.